Key stats
About T. Rowe Price Health Care ETF
Home page
Inception date
Jun 11, 2025
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
T. Rowe Price Associates, Inc. (IM)
Distributor
T. Rowe Price Investment Services, Inc.
TMED actively invests in securities of health care companies located mainly in the US but may also include foreign companies as well. Health care companies include a wide range such as biotechnology, pharmaceuticals, products and device providers, and health care service companies. Firms must be classified in the MSCI GICS health care sector. The fund employs a fundamental, bottom-up analysis and can invest in companies across any market capitalization using both growth and value strategies, typically focusing on 100-150 stocks. This includes the use of derivatives related to the fund's investment focus. The funds management team aims to outperform its respective sector index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.81%
Health Technology84.49%
Health Services8.03%
Distribution Services4.04%
Retail Trade1.68%
Finance1.10%
Technology Services0.37%
Electronic Technology0.03%
Bonds, Cash & Other0.19%
Mutual fund0.26%
Cash−0.07%
Stock breakdown by region
North America90.81%
Europe8.43%
Middle East0.40%
Asia0.36%
Latin America0.00%
Africa0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
TMED invests in stocks. The fund's major sectors are Health Technology, with 84.55% stocks, and Health Services, with 8.03% of the basket. The assets are mostly located in the North America region.
TMED top holdings are Eli Lilly and Company and AbbVie, Inc., occupying 13.76% and 6.32% of the portfolio correspondingly.
TMED assets under management is 10.82 M USD. It's risen 8.11% over the last month.
TMED fund flows account for 1.23 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, TMED doesn't pay dividends to its holders.
TMED shares are issued by T. Rowe Price Group, Inc. under the brand T. Rowe Price. The ETF was launched on Jun 11, 2025, and its management style is Active.
TMED expense ratio is 0.44% meaning you'd have to pay 0.44% of your investment to help manage the fund.
TMED follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
TMED invests in stocks.
TMED trades at a premium (0.02%) meaning the ETF is trading at a higher price than the calculated NAV.